Subject — expiring SEK 393M blood-gas framework: the retender window is opening
Blood-gas analysis instruments (Analysinstrument för blodgasmätning) — Karolinska Universitetssjukhuset / Region Stockholm. Framework awarded 2024-05-24 to Triolab AB, five lots, total SEK 393,000,000 ≈ €34.6M, every lot ending 2026-11-28. CPV 33190000 + 38432000/38434520 (analysis instruments). Award notice. This Note covers the ~4.5-month pre-retender window — the buyer must decide the lane's future before December.
2026-11-28all five lots end
fa-wo-rclane locked to holder since 2024
43%buyer's framework share (vs 88% at comparably sized ministries)
€34.6Mframework total (5 lots)
Finding 1 · The lane is closed by design — and the clock runs out in November
OBSERVED Both Triolab awards at this buyer carry framework code fa-wo-rc (framework without reopening of competition): the 5-lot blood-gas framework (ends 2026-11-28) and a further diagnostics contract (ends 2027-02). Call-offs under these are legally placed with the holder only.
DERIVED No competitive event has been possible in this lane since award (May 2024); none is possible until the vehicle ends.
INFERENCE · HIGH The end date is contractual, not indicative: all five lots terminate 2026-11-28. Under LOU (Swedish procurement act) and EU framework rules, a material extension of a fixed-term framework of this size is a modification that risks challenge — quiet prolongation is the legally exposed option, an open retender the safe one. Procurement lead times for instrument frameworks make Q3-Q4 2026 the expected notice window.
IMPLICATION Any supplier wanting this €34.6M lane has exactly one entry point: the retender. Vendor-side preparation (instrument certification, reagent logistics, Region Stockholm vendor registration) has a hard deadline of roughly Q4 2026.
VERIFY Watch Region Stockholm/Karolinska procurement channels (TendSign/Mercell listings) for the prior-information or contract notice; the buyer's planning typically surfaces 3-6 months pre-expiry.
Finding 2 · Who is Triolab — and who else already supplies this buyer
Supplier
Awards (36 mo)
Total (EUR)
Lane
Triolab AB
2
€36.0M (subject framework €34.6M + one further 2025 award €1.4M)
Blood-gas + diagnostics instruments
Cepheid AB
1
€41.8M
Molecular diagnostics
Sysmex Nordic ApS
1
€15.8M
Hematology
Hamilton Nordic AB
1
€13.6M
Lab automation
OBSERVED Karolinska's diagnostics spend is split across specialist distributors/OEM subsidiaries per discipline (Triolab, Cepheid, Sysmex, Hamilton — 36-month TED record).
DERIVED One-lane-one-specialist pattern; no single dominant house across disciplines.
INFERENCE · MEDIUM-HIGH The buyer runs discipline-specific contests and is demonstrably willing to contract different suppliers per lane — a challenger does not have to displace a house-wide incumbent, only win one discipline.
IMPLICATION For blood-gas OEMs (e.g. those distributed by competitors of the incumbent's portfolio), this is a winnable single-lane contest, not an ecosystem war.
VERIFY Confirm current instrument installed base and reagent lock-ins via clinical-lab publications or the original 2024 tender documents (Region Stockholm archive).
Finding 3 · Buyer behaviour — a competitive-culture contrast
OBSERVED 56 award notices in 36 months; 43% flagged framework/DPS. (For contrast: the buyer in our Note #001 showed 88%.)
DERIVED Karolinska awards a majority of its TED-visible contracts OUTSIDE standing vehicles.
INFERENCE · MEDIUM (36-month TED window only; below-threshold spend unobservable) Retender (rather than administrative renewal) is the culturally likely outcome for the expiring lane; this buyer runs open contests routinely.
IMPLICATION Challenger odds here are structurally better than at vehicle-first buyers; the November expiry is likely a genuine competitive event.
VERIFY Disclosure map (why this matters): eForms bid-statistics fields are populated differently per country — this Swedish notice publishes the medium-enterprise count only; Czech notices (Note #001) publish full totals. Cross-country bid-count comparison requires that normalization; the 2024 total for this contest sits in Region Stockholm's records (offentlighetsprincipen makes the request routine).
Finding 4 · What comparable Swedish lab-equipment awards look like
OBSERVED 16 of 18 Swedish CPV-3312* award notices since 2024 carry usable values.
INFERENCE · MEDIUM (corridor is adjacent-CPV context, not blood-gas-specific) Multi-year reagent-inclusive instrument frameworks are structurally larger than single-purchase lab awards: the €34.6M subject bundles instruments plus a 2.5-year consumables annuity across 5 lots, while the corridor (adjacent CPV, single awards) medians €852k. The corridor prices individual-lot expectations, not the framework class; expect the retender lot-structured as in 2024.
IMPLICATION Bid economics should be modelled per lot and on the reagent annuity, not the headline.
VERIFY Recompute against the retender's own lot structure when published.
Questions this Note cannot answer (and where to get them)
Who bid in the 2024 contest (total count undisclosed on TED for this notice)
Region Stockholm procurement records / tender archive (Swedish FOI — offentlighetsprincipen — is fast and strong)
Installed instrument base and reagent lock-in terms
2024 tender documents; clinical-lab community sources
National contract-registry layer (Czech-style Registr smluv)
Sweden has no central full-text contract register; per-region archives apply
Terms of use (liability management)
Nature of product
Market intelligence compiled algorithmically from official public records. NOT legal, procurement-compliance, or bid-submission advice; no advice is given.
Verification duty
Facts must be verified against the linked source notices and original tender documents before any bid decision. Every inference carries a confidence level and a verification path.
Known limits
TED covers above-threshold procedures; values as reported by buyers; Swedish notices in this period disclose partial bid statistics only; FX indicative (SEK 0.088).
Liability cap
Provider's aggregate liability is limited to the fee paid for this Note. No warranty of fitness for a particular bid outcome.
Licence
Internal use and client advisory by the purchasing organisation; public redistribution as-is not permitted. Source data remains CC BY 4.0 / open licences.